HCPCS Code J2765: Metoclopramide HCl injection billing guide

Key Takeaways

HCPCS Code J2765 describes injection of metoclopramide HCl (Reglan), up to 10 mg per billing unit, used for nausea, vomiting, and gastroparesis.

Each billing unit covers up to 10 mg. Practices administering a 20 mg dose must report two units of J2765 on the same claim line.

The JZ modifier became mandatory for J2765 on July 1, 2023, to confirm no drug was wasted. JW, which reports discarded drug waste, was already required for single-dose vial claims before that.

Practice management software like Pabau tracks injectable drug units, modifier requirements, and NDC data to reduce J2765 claim denials.

HCPCS Code J2765 describes “Injection, metoclopramide HCl, up to 10 mg,” as maintained by CMS, the Centers for Medicare and Medicaid Services. It falls under HCPCS Level II, category: Drugs Administered Other Than Oral Method. The short descriptor used on claims is “Metoclopramide hcl injection.”

Most claim denials on J2765 come down to three preventable mistakes: the wrong unit count, a missing modifier, or no NDC on the claim when the payer requires one. Because of this, IV therapy practice software that automates these fields at the point of documentation cuts that denial rate.

HCPCS code J2765 definition and clinical description

J2765 is a J-code, the subset of HCPCS Level II codes used in medical billing to identify injectable and infused drugs that patients do not take by mouth. Some billers mislabel it as “CPT code J2765,” but J2765 is a HCPCS Level II code, not a CPT code. In short, the CPT code covers the administration service, the injection itself, while the J-code identifies the drug product.

Metoclopramide hydrochloride (brand name Reglan) is a dopamine receptor antagonist that speeds gastric emptying and reduces nausea signaling. Clinicians give it by injection for acute nausea and vomiting, chemotherapy-induced nausea, gastroparesis, and gastroesophageal reflux.

The FDA has approved metoclopramide for these indications. However, it carries a black box warning for tardive dyskinesia with prolonged use, so billing records must reflect the approved indication and duration of therapy.

Dosage units, NDC reporting, and billing workflow

The most frequent coding error on J2765 claims is reporting the wrong number of units. Each unit of J2765 represents up to 10 mg of metoclopramide HCl. For example, a 20 mg dose requires two units, while a 5 mg dose still bills as one unit because the descriptor reads “up to 10 mg.”

Unit calculation rules

• Up to 10 mg: bill 1 unit of J2765
• 11 mg to 20 mg: bill 2 units of J2765
• 21 mg to 30 mg: bill 3 units of J2765
• Round up to the next whole unit when the dose does not divide evenly into 10 mg increments
• Document the exact mg administered in the clinical note; the billed units must reconcile with the documented dose

NDC reporting requirements

Many payers, including Medicaid programs and some Medicare Advantage plans, require the National Drug Code (NDC) on the claim line alongside J2765. Report the NDC in 11-digit format (5-4-2: labeler-product-package).

When an NDC is required, include the unit of measurement qualifier (e.g., ML for milliliter) and the quantity dispensed in the appropriate claim field (Box 24D on a CMS-1500 form or the equivalent 837P loop). Claims management software that stores NDC data at the drug inventory level prevents staff from looking up the NDC each time metoclopramide is administered.

Place of service codes

J2765 is administered in multiple settings. The Place of Service (POS) code affects reimbursement rates under Medicare:

• POS 11 (Office): standard physician fee schedule rate applies
• POS 22 (Outpatient Hospital): subject to OPPS/APC payment methodology
• POS 19 (Off-Campus Outpatient Hospital): OPPS rates apply
• POS 65 (End-Stage Renal Disease Facility): bundled into ESRD composite rate in many cases
• POS 21 (Inpatient Hospital): typically bundled into DRG; do not bill J2765 separately

Good injectable drug inventory management keeps lot numbers and NDC identifiers linked to each vial so the correct NDC populates the claim automatically, regardless of which staff member administered the dose. Emergency department administrations often pair J2765 with an E/M level such as CPT 99284 for the visit itself.

Fee schedule and Medicare reimbursement rates

Medicare reimburses J2765 under the Part B drug payment method. The payment rate builds on the Average Sales Price (ASP) of metoclopramide HCl, which CMS calculates quarterly and publishes in the ASP Drug Pricing Files. Under Medicare Part B, the standard rate for most Part B drugs is ASP plus 6% for physician-administered drugs in an office setting.

Metoclopramide is a low-cost generic. Recent CMS ASP-based payment allowances for J2765 have run roughly $0.95 to $1.10 per unit, though the exact current rate depends on the quarterly ASP update and varies each quarter. Practices should check the CMS fee schedule tool for the current applicable rate before submitting claims.

Practices that handle J2765 billing alongside other injectable drugs should also follow HIPAA compliance requirements that extend to how drug administration records are stored and transmitted on claims. Accurate, complete documentation at the point of care directly supports clean claim submission.

Stop chasing J2765 denials with manual workarounds

Pabau's claims management tools track injectable drug units, modifiers, and NDC data at the point of documentation so your billing team submits clean claims the first time.

Book a demo

JW and JZ modifier requirements for J2765

CMS requires either the JW modifier or the JZ modifier on all Part B single-dose container drug claims, including J2765. JW has long been required to report discarded drug waste, and JZ became mandatory on July 1, 2023, to confirm no waste occurred.

This policy applies when metoclopramide is drawn from a single-dose vial (SDV). Failing to append one of these modifiers is a technical denial trigger under Medicare.

JW modifier: Drug waste reporting

You append the JW modifier to a second J2765 line on the claim to report the amount of drug discarded from a single-dose vial. For example, if a vial contains 10 mg and the clinician gives only 7 mg, you must record the 3 mg of unused drug and bill it on a separate line with JW.

• Line 1: J2765, 1 unit (7 mg administered, rounded up to 10 mg billing unit)
• Line 2: J2765, JW modifier, units representing the discarded portion
• Both lines must tie to the same date of service and same administration event
• Clinical documentation must record the lot number, vial size, mg administered, and mg wasted

JZ modifier: No waste attestation

When staff use a single-dose vial completely with no drug wasted, you append the JZ modifier to the J2765 claim line. This attests to the payer that the patient received the entire vial contents and no waste occurred. You then need only one line when JZ applies.

Multi-dose vials (MDVs) are exempt from the JW/JZ modifier requirement, but a true multi-dose, preservative-containing metoclopramide product is rare to nonexistent in current US NDC listings. Default to treating metoclopramide as single-dose (SDV) status, and verify the NDC before ever treating a J2765 claim as MDV-exempt.

Misclassifying an SDV as an MDV to avoid the modifier requirement can trigger a compliance audit. Robust prescription management software that distinguishes SDV from MDV at the drug level reduces this risk at the point of documentation.

Supporting ICD-10 diagnosis codes and medical necessity

Payers require the ICD-10-CM diagnosis code on the claim to establish medical necessity for J2765. The diagnosis code must reflect the clinical indication documented in the patient record and align with the FDA-approved or payer-accepted indications for metoclopramide injection. Digital clinical forms that capture the indication at the point of consultation keep documentation and billing aligned.

When metoclopramide supports antiemetic control during chemotherapy, cross-check the administration code too. Chemotherapy IV infusion often bills under CPT 96413, while subcutaneous or intramuscular chemo administration uses CPT 96401. Antineoplastic drugs without a specific J-code fall under J9999.

Off-label use of metoclopramide injection may require a letter of medical necessity (LMN) from the treating physician before payer approval, with the clinical rationale documented and peer-reviewed literature cited for indications outside the standard list.

Practices running an IV therapy program should maintain a standard intake process that captures the diagnosis before treatment begins, following IV therapy best practices for documentation.

Prior authorization and payer-specific requirements

Traditional Medicare does not require prior authorization for J2765 in most settings. Prior authorization is more likely to be required by:

• Medicare Advantage plans: many MA plans apply formulary management that requires PA for injectable antiemetics, including metoclopramide
• UnitedHealthcare Exchange Plans: J2765 appears on the UHC Exchange Plans prior authorization list. Verify current requirements directly with UHC, as lists are updated annually
• Medicaid managed care organizations (MCOs): MCOs apply their own drug management policies that vary significantly by state and plan
• Commercial payers: check the provider portal or contact the payer before the first claim if your practice does not regularly bill J2765

Practices that run structured drug authorization workflows as part of their IV therapy EMR software can flag J2765 patients requiring PA before the appointment rather than after a denial. Tracking authorization numbers in the patient record and linking them to the claim reduces avoidable rework for the billing team.

Common J2765 billing errors and how to avoid them

Most J2765 denials fall into a small number of repeating categories. Identifying the denial pattern on your remittance advice before resubmitting saves time and prevents the same error recurring on future claims.

One avoidable error sits upstream of the claim: billing an unclassified drug code such as J3490 or J7999 when the specific code J2765 exists. Payers route unclassified J-code claims to manual review, so always report J2765 for metoclopramide injection rather than a miscellaneous code.

Missing or incorrect modifier

Submitting J2765 without JW or JZ on a single-dose vial claim results in a technical denial under Medicare. The fix is straightforward: add the appropriate modifier and resubmit. Going forward, build a billing rule or claim scrubber that flags any J2765 claim missing both modifiers when the drug is sourced from an SDV.

Unit count mismatch

A claim showing one unit of J2765 when the clinical note documents a 20 mg administration will trigger a medical necessity review or denial on audit. Reconcile billed units against administered milligrams during the pre-claim review step. The automated billing workflows inside practice management platforms can run this check at point of charge entry.

Missing NDC when required

Medicaid and some MA plans reject J2765 claims that lack the NDC. Store the NDC for each metoclopramide product your practice stocks at the inventory level so it populates automatically on drug-related claims.

For practices running an IV therapy clinic as a core service line, an NDC library tied to your formulary is a practical necessity, not a nice-to-have.

Diagnosis code not supporting medical necessity

Using a diagnosis code that a payer does not recognize as a supported indication for metoclopramide injection results in a medical necessity denial. Cross-reference the ICD-10 codes in the table above with your payer’s coverage policy before submitting.

The AAPC HCPCS lookup tool and PGM Billing’s HCPCS lookup provide crosswalk data that can help identify acceptable diagnosis pairings for J2765.

The same cross-referencing logic applies to other injectable drug HCPCS codes, such as Q5104 for infliximab-abda claims.

Practices running a structured IV therapy patient intake workflow that captures the clinical indication in a templated form before treatment keep documentation and claims aligned. When the intake form ties directly to the clinical record and billing system, diagnosis selection becomes part of the clinical workflow instead of a billing-team afterthought.

Getting J2765 claims right the first time

Most J2765 denials share a common root: documentation that does not match what ends up on the claim. Unit counts, modifier selection, NDC data, and diagnosis codes all need to reconcile with the clinical record before submission.

Practices that align documentation with the claim at the point of care, rather than fixing it in the billing queue, recover more revenue and spend less time on rework.

Pabau’s practice management software captures injectable drug details, modifier flags, and NDC data during documentation so claims go out clean. If your team is still managing J2765 billing manually, compare options in our medical billing software guide, or book a demo to see how Pabau handles injectable drug claims from administration through submission.

Continue your research

Looking to reduce claim denials across all procedure codes? Mobile IV therapy operations covers the billing infrastructure and compliance requirements for mobile and outpatient injectable drug services.

Frequently Asked Questions